APA (7th ed.) Citation

Mai, E. K., Goldschmidt, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., . . . Salwender, H. (2024). Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): Results from a randomised, phase 3 trial. The lancet. Haematology, 11(2), . https://doi.org/10.1016/S2352-3026(23)00366-6

Chicago Style (17th ed.) Citation

Mai, Elias K., et al. "Elotuzumab, Lenalidomide, Bortezomib, Dexamethasone, and Autologous Haematopoietic Stem-cell Transplantation for Newly Diagnosed Multiple Myeloma (GMMG-HD6): Results from a Randomised, Phase 3 Trial." The Lancet. Haematology 11, no. 2 (2024). https://doi.org/10.1016/S2352-3026(23)00366-6.

MLA (9th ed.) Citation

Mai, Elias K., et al. "Elotuzumab, Lenalidomide, Bortezomib, Dexamethasone, and Autologous Haematopoietic Stem-cell Transplantation for Newly Diagnosed Multiple Myeloma (GMMG-HD6): Results from a Randomised, Phase 3 Trial." The Lancet. Haematology, vol. 11, no. 2, 2024, https://doi.org/10.1016/S2352-3026(23)00366-6.